CARGO Therapeutics, Inc. Common Stock

NasdaqGS CRGX

CARGO Therapeutics, Inc. Common Stock Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -140.63 M

CARGO Therapeutics, Inc. Common Stock Free Cash Flow is USD -140.63 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -99.26% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • CARGO Therapeutics, Inc. Common Stock Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -70.57 M.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
NasdaqGS: CRGX

CARGO Therapeutics, Inc. Common Stock

CEO Ms. Gina Chapman
IPO Date Nov. 13, 2023
Location United States
Headquarters 1900 Alameda De Las Pulgas
Employees 170
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

StockViz Staff

January 15, 2025

Any question? Send us an email